Background Heart failure presents a growing clinical and economic burden in the USA.
Robust cost data on the burden of illness are critical to inform economic evaluations of new …

BACKGROUND: Heart failure (HF) affects approximately 6 million Americans, with
prevalence projected to increase by 46% and direct medical costs to reach 53billionby2030.Hospitalizationsarethelargestcomponentofd …

Background: Epidemiology of patients with worsening heart failure and reduced ejection
fraction (HFrEF) in the real-world setting is not well described. Objectives: The purpose of …

Objectives: The objective of this study was to determine the cost-effectiveness and cost per
quality-adjusted life year (QALY) gained of sacubitril-valsartan relative to enalapril for …

Introduction A worsening heart failure event (WHFE) is defined as progressively escalating
heart failure signs/symptoms requiring intravenous diuretic treatment or hospitalization. No …

Objective Given the high economic burden of disease among adult patients with chronic
heart failure with reduced ejection fraction (HFrEF) following a worsening heart failure event …

Aims Heart failure (HF) is a chronic and progressive syndrome associated with a poor
prognosis. While it may seem intuitive that the risk of adverse outcomes varies across the …

Both heart failure and diabetes are increasing in prevalence in Western communities. The
interrelationship between these two conditions is well known, with conventional heart failure …

In clinical practice, many patients with heart failure with reduced ejection fraction (HFrEF)
are either not prescribed guideline-directed medical therapies for which they are eligible or …

Introduction In the USA, patients with chronic heart failure (HF) with reduced ejection fraction
(HFrEF) following a worsening HF event (WHFE) have significantly increased healthcare …